Pharmacophore an International Research Journal
Irbesartan is classified as an angiotensin II receptor type 1 antagonist. Angiotensin II receptor type 1 antagonists are widely used in treatment of diseases like hypertension, heart failure, myocardial infarction and diabetic nephropathy. Irbesartan is an orally active lipophilic drug and possesses rapid oral absorption. It causes reduction in blood pressure and is used in treatment of hypertension. Irbesartan delays progression of diabetic nephropathy and is indicated for the reduction of renal disease progression
in patients with type 2 diabetes. It is jointly marketed by Sanofi-Aventis and Bristol-Myers Squibb under the trade name Aptovel®, Karvea® and Avapro®. Irbesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. This paper reviews the pharmacological and pharmaceutical properties of Irbesartan. Irbesartan could be an attractive target for the generic industries.
